93 results on '"Canella, Alessandro"'
Search Results
2. Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment
3. Single-cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma
4. LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators
5. Protein acetylation in cardiac aging
6. BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics in vivo
7. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers
8. Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity
9. Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations
10. C(5) modified uracil derivatives showing antiproliferative and erythroid differentiation inducing activities on human chronic myelogenous leukemia K562 cells
11. Effective Hemostasis During Minor Surgery in a Case of Hereditary Combined Deficiency of Vitamin K-dependent Clotting Factors
12. Development of K562 cell clones expressing β-globin mRNA carrying the β039 thalassaemia mutation for the screening of correctors of stop-codon mutations
13. Influence of obstetric factors on osteogenic potential of umbilical cord-derived mesenchymal stem cells
14. 1-03 Role of Activin A in human cancer cachexia (ACTICA study)
15. The pan-HDAC inhibitor AR42 downregulates CD44 expression, a new circulating prognostic factor for multiple myeloma
16. PB1704: LEDGF/P75 ASSOCIATED WITH CHEMORESISTANCE IN MIXED-LINEAGE LEUKEMIA.
17. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
18. Readthrough of the premature stop codon beta039-thalassemia
19. The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity
20. RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations
21. Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype
22. Production of β-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β°39 thalassemia patients
23. High Porosity Bioceramic is a Favourable Environment for the Adhesion and Proliferation of Human Mesenchymal Stem Cells
24. Non-conventional therapeutic strategies for inherited disorders oh hemostasis
25. Production of s-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous s039 thalassemia patients
26. Formation of L-Threonic Acid from L-Ascorbic Acid Oxidative Ring Opening and its Coordination to PtII: X-ray Crystal Structures of [Pt(threonato-O,O)-(PPh3)2] and [Pt(oxalato)(PPh3)2]
27. Non-conventional therapeutic strategies for inherited disorders of hemostasis
28. Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants
29. Interaction of occupational posture, lifestyle and genetic components of thrombophilia
30. Proteasome inhibitors: synthesis and activity of arecoline oxide tripeptide derivatives
31. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals
32. Hybrid α-bromoacryloylamido chalcones. Design, synthesis and biological evaluation
33. The potential diagnostic power of extracellular vesicle analysis for multiple myeloma.
34. Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers
35. Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development
36. HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide
37. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7.
38. Characterization of multiple myeloma vesicles by label-free relative quantitation.
39. Production of β-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β039 thalassemia patients.
40. The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity.
41. Effect of interferon-α therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals.
42. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
43. Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival.
44. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors.
45. Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
46. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
47. Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
48. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
49. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
50. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.